RecruitingPhase 2NCT06587802

Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

Studying Adrenocortical carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Shengjie Guo, doctor
Intervention
Triprolizumab(drug)
Enrollment
18 enrolled
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06587802 on ClinicalTrials.gov

Other trials for Adrenocortical carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adrenocortical carcinoma

← Back to all trials